Seleccione idioma:  
RTICC 2013
Programas RTICC
Seguimiento cientifico

Coordinador: Dr. Luis Montuenga Badia
Centro: Centro para la Investigación Médica Aplicada
Dirección postal: Avda. Pío XII, 55, 31008, Pamplona
Email: lmontuenga[arroba]unav.es

Breve CV: Dr. Luis M. Montuenga got his undergraduate degree with Honors in Biology from the University of Navarra (Spain). He also has a Master of Sciences (MSc) in Neuroendocrine Cell Biology from University College London (UK). In 1984 got his Ph.D. in Biology from the University of Navarra (Spain). He spent two years as postgraduate fellow at the Royal Postgraduate Medical School in London and was Visiting Scientist at the National Cancer Institute (NIH) in Bethesda (Maryland) during three years (1995-1998). He is currently Full Professor of Cell Biology at the School of Medicine of the University of Navarra and Senior Researcher and Head of the Oncology Division of the Center for Applied Medical Research (CIMA), University of Navarra. In the past Dr. Montuenga has been the Head of the Histology and Pathology Department of the School of Medicine (1998-2007) and Vicepresident of Research of the University of Navarra (2008-2011). 

Dr. Montuenga has authored more than 120 peer-reviewed publications in Cell Biology and Oncology, has directed 18 doctoral theses and has given numerous conferences and seminars internationally. His research activity is primarily focused on lung cancer. At the Center of Applied Medical Research he co-leads, together with Dr. Ruben Pio, the Laboratory of Lung Cancer Biomarkers. The laboratory of Biomarker’s is focused on the molecular mechanisms associated with the transformation of normal lung epithelial cells into lung tumors. One of its main translational aims is to find molecular markers related to lung carcinogenesis to develop new strategies for lung cancer early detection. Other research interest of the group is to design new molecular targeted therapies that may be useful in the treatment of lung tumors.

He has served as ad hoc reviewer in a variety of national and international research evaluation agencies and has been involved in the peer review process of a large number of journals of his research field.  He is currently Associate Editor of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

He is founding member of the European Union Early Lung Cancer (EUELC), member of the prevention Committee of the IASLC, Active member of the American Association for Cancer Research (AACR) and the European Respiratory Society as well as Spanish scientific research societies like the Asociación Española de Investigación en Cáncer (ASEICA) or the Spanish Society for Cell Biology (SEBC).

In the past editions of the RTICC network, Dr. Montuenga has been the Coordinator for Training and Mobility and now serves as Coordinator of the Respiratory Tract Tumors Program.

Work Packages
Ensayos clínicos
Otros resultados
The impact of the regimen of screening on lung cancer cure: a comparison of I-ELCAP and NLST.
Yip R, Henschke CI, Yankelevitz DF, Boffetta P, Smith JP, International Early Lung Cancer Investigators
Eur J Cancer Prev  2015.  3.  201-8.  PMID: 25089376. 

Improving selection criteria for lung cancer screening. The potential role of emphysema.
Sanchez-Salcedo P, Wilson DO, de-Torres JP, Weissfeld JL, Berto J, Campo A, Alcaide AB, Pueyo J, Bastarrika G, Seijo LM, Pajares MJ, Pio R, Montuenga LM, Zulueta JJ
Am J Respir Crit Care Med  2015.  8.  924-31.  PMID: 25668622. 
Grupos colaboradores: RD12/0036/0062 , RD12/0036/0040

Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.
Ajona D, Razquin C, Pastor MD, Pajares MJ, Garcia J, Cardenal F, Fleischhacker M, Lozano MD, Zulueta JJ, Schmidt B, Nadal E, Paz-Ares L, Montuenga LM, Pio R
PLoS One  2015.  3.  e0119878.  PMID: 25799154. 
Grupos colaboradores: RD12/0036/0045 , RD12/0036/0028 , RD12/0036/0062 , RD12/0036/0040

Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients.
Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R, Montuenga LM
PLoS One  2015.  4.  e0124670.  PMID: 25915617. 

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial.
Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, Massacesi L, Di Gioia M, Vuolo L, Currò D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P, Farge D, Saccardi R, ASTIMS Haemato-Neurological Collaborative Group, On behalf of the Autoimmune Disease Working Party (ADWP) of the European Group for Blood and Marrow Transplantation (EBMT), ASTIMS Haemato-Neurological Collaborative Group On behalf of the Autoimmune Disease Working Party ADWP of the European Group for Blood and Marrow Transplantation EBMT
Neurology  2015.  10.  981-8.  PMID: 25672923. 

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.
Rosiñol L, Jiménez R, Rovira M, Martínez C, Fernández-Avilés F, Marín P, Suárez-Lledó M, Gutiérrez-García G, Fernández de Larrea C, Carreras E, Urbano-Ispizua A, Bladé J
Bone Marrow Transplant  2015.  PMID: 25621810. 

How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.
Carreras E
Br J Haematol  2015.  4.  481-91.  PMID: 25401997. 

Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34(+) cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Martino R, Bautista G, Parody R, García I, Esquirol A, Rovira M, Cabrera JR, Regidor C, Fores R, García-Marco JA, Serrano D, Barba P, Heras I, Marquez-Malaver FJ, Sánchez-Ortega I, Duarte R, Saavedra S, Sierra J, Vazquez L, Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH)
Transpl Infect Dis  2015.  2.  221-33.  PMID: 25652036. 
Grupos colaboradores: RD12/0036/0069 , RD12/0036/0071 , RD12/0036/0046 , RD12/0036/0052

Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP).
Snarski E, Snowden JA, Oliveira MC, Simoes B, Badoglio M, Carlson K, Burman J, Moore J, Rovira M, Clark RE, Saiz A, Hadj-Khelifa S, Tan J, Crescimanno A, Musso M, Martin T, Farge D
Bone Marrow Transplant  2015.  2.  216-20.  PMID: 25387098. 

Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.
Parody R, Martino R, de la Cámara R, García-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Avilés F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sánchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L
Bone Marrow Transplant  2015.  2.  274-81.  PMID: 25347007. 
Grupos colaboradores: RD12/0036/0069 , RD12/0036/0071 , RD12/0036/0046 , RD12/0036/0052

Ministerio de Economia y Competitividad
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos